MedTrace Logo

BEst Size for Ovulation Triggering in Poseidon 4 Patients (BEST 4 Study)

NCT06433518 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-03-19

No results posted yet for this study

Summary

This observational clinical study aims to determine the optimal timing of ovulation triggering in women aged 35 and above with poor ovarian reserve.

For this purpose, cases undergoing ovarian stimulation for assisted reproductive treatment and planned final oocyte triggering will be evaluated in two separate groups:

1. \*\*Experimental Group\*\*: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm.
2. \*\*Control Group\*\*: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm.

All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections.

The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates.

Primary and secondary outcomes will be compared between the two groups.

Conditions

  • Fertilization
  • Fertilization in Vitro

Interventions

OTHER

Ovulation Trigger Timing Based on Leading Follicle Size in POSEIDON Group 4 IVF Patients

In this study, ovulation trigger timing is determined according to the diameter of the leading follicle measured by transvaginal ultrasound during ovarian stimulation in women classified as POSEIDON group 4. Patients undergoing controlled ovarian stimulation are monitored with serial ultrasound examinations and serum hormone measurements. Ovulation triggering is performed when the leading follicle reaches predefined size categories. The study evaluates the association between the diameter of the leading follicle at the time of trigger and reproductive outcomes. The primary outcome measure is the number of metaphase II (MII) oocytes retrieved, while secondary outcomes include blastocyst formation and pregnancy outcomes.

Sponsors & Collaborators

  • Centrum Clinic IVF Center

    lead OTHER

Principal Investigators

  • Emre Pabuccu, Prof. · Ufuk University

Eligibility

Min Age
35 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-15
Primary Completion
2026-12-01
Completion
2026-12-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06433518 on ClinicalTrials.gov